Numerous clinical observations indicate that, despite novel therapeutic approaches, a high percentage of melanoma patients is non-responder or suffers of severe drug-related toxicity. To overcome these problems, we considered the option of designing, preparing and characterizing nanoemulsions and niosomes containing oleic acid, a pH-sensitive monounsaturated fatty acid holding per se an antimetastatic and anti-inflammatory role in melanoma. These new nanostructures will allow in vivo administration of oleic acid, otherwise toxic in its free form. For pulmonary route chitosan, a mucoadhesive agent, was enclosed in these nanocarriers to improve residence time at the lung site. A deep physical and chemical characterization was carried out evaluating size, ζ -potential, microviscosity, polarity as well as stability over time and in culture media. Moreover, their pHsensitivity was evaluated by fluorometric assay. Cytotoxicity and cellular uptake were assessed in cultured normal fibroblasts and human melanoma cell lines. Interestingly, results obtained confirm nanocarrier stability and pH-sensitivity, associated to absence of cell toxicity, efficient cellular uptake and retention. Therefore, these new pH-sensitive oleic acid-based nanostructures could represent, by combining drug delivery in a pH-dependent manner with the antimetastatic potential of this fatty acid, a powerful strategy for more specific medicine against metastatic melanoma.

pH-responsive oleic acid based nanocarriers. Melanoma treatment strategies / Rinaldi, Federica; Forte, Jacopo; Pontecorvi, Giada; Hanieh, Patrizia Nadia; Carè, Alessandra; Bellenghi, Maria; Tirelli, Valentina; Grazia Ammendolia, Maria; Mattia, Gianfranco; Marianecci, Carlotta; Puglisi, Rossella; Carafa, Maria. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. X. - ISSN 2590-1567. - 613:(2022), pp. 1-13. [10.1016/j.ijpharm.2021.121391]

pH-responsive oleic acid based nanocarriers. Melanoma treatment strategies

Federica Rinaldi
Primo
;
Jacopo Forte
Secondo
;
Patrizia Nadia Hanieh;Carlotta Marianecci
;
Maria Carafa
Ultimo
2022

Abstract

Numerous clinical observations indicate that, despite novel therapeutic approaches, a high percentage of melanoma patients is non-responder or suffers of severe drug-related toxicity. To overcome these problems, we considered the option of designing, preparing and characterizing nanoemulsions and niosomes containing oleic acid, a pH-sensitive monounsaturated fatty acid holding per se an antimetastatic and anti-inflammatory role in melanoma. These new nanostructures will allow in vivo administration of oleic acid, otherwise toxic in its free form. For pulmonary route chitosan, a mucoadhesive agent, was enclosed in these nanocarriers to improve residence time at the lung site. A deep physical and chemical characterization was carried out evaluating size, ζ -potential, microviscosity, polarity as well as stability over time and in culture media. Moreover, their pHsensitivity was evaluated by fluorometric assay. Cytotoxicity and cellular uptake were assessed in cultured normal fibroblasts and human melanoma cell lines. Interestingly, results obtained confirm nanocarrier stability and pH-sensitivity, associated to absence of cell toxicity, efficient cellular uptake and retention. Therefore, these new pH-sensitive oleic acid-based nanostructures could represent, by combining drug delivery in a pH-dependent manner with the antimetastatic potential of this fatty acid, a powerful strategy for more specific medicine against metastatic melanoma.
2022
drug delivery; niosomes; nanoemulsions; ph sensitivity; metastatization; fatty acids
01 Pubblicazione su rivista::01a Articolo in rivista
pH-responsive oleic acid based nanocarriers. Melanoma treatment strategies / Rinaldi, Federica; Forte, Jacopo; Pontecorvi, Giada; Hanieh, Patrizia Nadia; Carè, Alessandra; Bellenghi, Maria; Tirelli, Valentina; Grazia Ammendolia, Maria; Mattia, Gianfranco; Marianecci, Carlotta; Puglisi, Rossella; Carafa, Maria. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. X. - ISSN 2590-1567. - 613:(2022), pp. 1-13. [10.1016/j.ijpharm.2021.121391]
File allegati a questo prodotto
File Dimensione Formato  
Rinaldi_pH-responsive_2022.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 7.05 MB
Formato Adobe PDF
7.05 MB Adobe PDF   Contatta l'autore
Rinaldi_Suppl. data_pH-responsive_2022.pdf

solo gestori archivio

Note: supplementary material
Tipologia: Altro materiale allegato
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.09 MB
Formato Adobe PDF
1.09 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1618585
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 14
social impact